Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8790127 | Urologic Oncology: Seminars and Original Investigations | 2018 | 6 Pages |
Abstract
Determinants of aXRT delivery in stage III PC appear to be related to the proximity to community cancer centers and greater nodal burden. We find evidence of a survival benefit with the use of aXRT, particularly in those with higher nodal stage. Multi-institutional studies are needed to confirm these findings and improve treatment algorithms for high-stage PC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Brian R. M.D., James T. M.D., Sarah K. Ph.D., Matthew M.D., Daniel W. M.D., Jonathan L. M.D., M.S.,